Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ADMA Biologics (ADMA)
NASDAQ:ADMA
Holding ADMA?
Track your performance easily
Earnings Data
Report Date
Mar 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.16Last Year’s EPS
-$0.08Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -11.76%
|Next Earnings Date:Mar 20, 2025
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance with significant growth in revenue, EBITDA, and net income. The company revised its financial guidance upwards and highlighted strategic initiatives such as ASCENIV's production shift and ADMAlytics implementation. However, challenges persist with gross margin impacts from low-margin plasma sales, discontinuation of a product line, and supply constraints for ASCENIV.Company Guidance
During the ADMA Biologics Q3 2024 earnings call, the company provided an optimistic financial outlook with several key metrics illustrating its strong performance and future projections. Total revenues for the third quarter reached $119.8 million, marking a 78% increase year-over-year. Adjusted EBITDA soared to $45.4 million, a 256% rise from the previous year, while net income surged by 1,300% to $35.9 million. The company revised its financial guidance upwards, expecting total revenues to exceed $415 million in 2024 and $465 million in 2025, with adjusted EBITDA projected to surpass $160 million and $215 million, respectively. Additionally, ADMA forecasted GAAP net income to be more than $120 million in 2024 and $165 million in 2025. The company anticipates substantial margin expansion driven by a revenue shift towards ASCENIV, foreseeing it as a potential $1 billion revenue opportunity with growth extending into the 2030s.Record Revenue Growth
Total revenues reached $119.8 million, reflecting an increase of 78% year-over-year.
Significant Adjusted EBITDA Increase
Adjusted EBITDA rose to $45.4 million, representing a growth rate of 256% from the previous year.
Remarkable Net Income Growth
Net income increased by 1,300% year-over-year to $35.9 million.
Upward Revision of Financial Guidance
ADMA revised its financial guidance upwards for both 2024 and 2025, with total revenues expected to exceed $415 million in 2024 and $465 million in 2025.
Strategic Shift Towards High-Growth ASCENIV
ASCENIV is projected as a potential $1 billion revenue opportunity with strategic shifts in production.
Successful Implementation of ADMAlytics
The AI and machine learning platform has increased production efficiency, enhanced manufacturing visibility, and optimized commercial planning.
---
ADMA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ADMA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $19.72 | $22.62 | +14.71% |
| Aug 08, 2024 | $12.19 | $15.96 | +30.93% |
| May 09, 2024 | $6.93 | $8.81 | +27.13% |
| Feb 28, 2024 | $5.38 | $5.36 | -0.37% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does ADMA Biologics (ADMA) report earnings?
ADMA Biologics (ADMA) is schdueled to report earning on Mar 20, 2025, TBA Not Confirmed.
What is ADMA Biologics (ADMA) earnings time?
ADMA Biologics (ADMA) earnings time is at Mar 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ADMA EPS forecast?
ADMA EPS forecast for the fiscal quarter 2024 (Q4) is $0.16.
---